Insights Cloud fosters healthy relationships between sponsors and CROs through greater transparency
PHILADELPHIA, PA – ERT, a leading eClinical solutions provider, including high-quality patient data collection and analysis, today announced enhancements to its Insights Cloud trial oversight solution that enable trial sponsors and clinical research organizations (CROs) to collaborate by sharing electronic monitoring visit reports and comprehensive issue management, tracking, and reporting. Insights Cloud brings simplicity to complex relationships by providing the transparency, accountability and flexibility that sponsors and CROs require to meet their shared goals. In addition to integrating data from all trial sources to deliver performance analytics, the solution is now using these same concepts to drive monitoring workflows and leverage data captured in trip reports as new electronic data assets. Protocol deviations and violations, site issues, and action items are electronically captured and integrated into Insights Cloud, providing a new layer of transparency and enabling sponsors and CROs to comply with emerging ICH E6 (R2) standards for adopting a more comprehensive approach to quality risk-based monitoring. “Sponsors and CROs are seeking new ways to simplify their relationships and to proactively mitigate risk in order to gain drug development efficiencies,” said Amy Furlong, Executive Vice President of eClinical Insights at ERT. “Insights Cloud’s enhanced trial oversight solution creates transparency among both parties, promoting collaboration and accountability to reduce issue resolution cycle times so they can move forward quickly, with confidence.” ERT is hosting a webinar on September 28 to demonstrate how sponsors and CROs can leverage the enhanced solution to drive efficiencies in clinical development. Registration details are available
here
. For additional information on Insights Cloud, visit
http://www.ert.com/insights-cloud
.
About ERT
ERT is a leading provider of high-quality patient data collection solutions for use in clinical drug development. ERT delivers a combination of technology, services and clinical consulting that increase the accuracy and reliability of patient data and improve the efficiency of the clinical development process. ERT delivers widely deployed solutions in centralized Cardiac Safety, Respiratory, and electronic Clinical Outcome Assessments (eCOA) – which includes patient-, clinician-, observer- and performance-reported outcomes – and cloud-based analytics and performance metrics. By efficiently integrating these solutions through a system built upon a scientific and regulatory foundation, ERT collects, analyzes and delivers safety and efficacy data critical to the approval, labeling and reimbursement of pharmaceutical products. For more information see
www.ert.com
. Join ERT on
,
,
YouTube
and
.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.